NATALIE MARIE DERSE, the CFO of $GEN, sold 794 shares of the company on 02-17-2026 for an estimated $18,754. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.2% of their shares of this class of stock. Following this trade, they now own 456,678 shares of this class of $GEN stock.
$GEN Insider Trading Activity
$GEN insiders have traded $GEN stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $GEN stock by insiders over the last 6 months:
- ONDREJ VLCEK sold 113,674 shares for an estimated $3,082,929
- JOHN C CHRYSTAL purchased 5,000 shares for an estimated $135,693
- NATALIE MARIE DERSE (CFO) sold 794 shares for an estimated $18,754
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GEN Hedge Fund Activity
We have seen 337 institutional investors add shares of $GEN stock to their portfolio, and 348 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 23,514,492 shares (-74.8%) from their portfolio in Q4 2025, for an estimated $639,359,037
- PACER ADVISORS, INC. removed 3,846,840 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $104,595,579
- FIRST TRUST ADVISORS LP added 3,640,451 shares (+22.3%) to their portfolio in Q4 2025, for an estimated $98,983,862
- CITADEL ADVISORS LLC added 3,213,739 shares (+606.6%) to their portfolio in Q4 2025, for an estimated $87,381,563
- NUVEEN, LLC removed 3,079,851 shares (-22.3%) from their portfolio in Q4 2025, for an estimated $83,741,148
- QUBE RESEARCH & TECHNOLOGIES LTD removed 2,786,250 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $75,758,137
- ALYESKA INVESTMENT GROUP, L.P. added 2,583,582 shares (+inf%) to their portfolio in Q4 2025, for an estimated $70,247,594
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$GEN Revenue
$GEN had revenues of $1.2B in Q3 2026. This is an increase of 25.76% from the same period in the prior year.
You can track GEN financials on Quiver Quantitative's GEN stock page.
$GEN Congressional Stock Trading
Members of Congress have traded $GEN stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $GEN stock by members of Congress over the last 6 months:
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 10/22.
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$GEN Analyst Ratings
Wall Street analysts have issued reports on $GEN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 11/07/2025
To track analyst ratings and price targets for $GEN, check out Quiver Quantitative's $GEN forecast page.
$GEN Price Targets
Multiple analysts have issued price targets for $GEN recently. We have seen 5 analysts offer price targets for $GEN in the last 6 months, with a median target of $32.0.
Here are some recent targets:
- Saket Kalia from Barclays set a target price of $32.0 on 02/06/2026
- Matthew Hedberg from RBC Capital set a target price of $29.0 on 11/07/2025
- Robert Coolbrith from Evercore ISI Group set a target price of $37.0 on 11/07/2025
- Joseph Gallo from Jefferies set a target price of $31.0 on 10/03/2025
- Hamza Fodderwala from Morgan Stanley set a target price of $32.0 on 09/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
